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ABSTRACT 
Extended-spectrum beta-lactamases (ESBLs) are plasmid-mediated beta-lactamases that are capable of 
hydrolysing β-lactams except carbapenems and cephamycins. The global increased prevalence of ESBL-
producing bacteria creates an urgent need for laboratory diagnostic methods that will accurately and rapidly 
identify the presence of ESBL phenotypes in clinical isolates. The Vitek 2 System (bioMérieux, France) is a 
rapid automated microbiological system used for bacteria and yeast identification, antimicrobial susceptibility 
testing (AST), resistance mechanism detection and epidemiologic trending and reporting using its advanced 
expert system. This present work sought to determine the reliability of routinely using Vitek 2 System to 
accurately and rapidly detect ESBL-producing E. coli and K. pneumoniae in Accra. The ESBL phenotypes for 
400 E. coli and K. pneumoniae isolates were determined using the Vitek 2 system and combined disc synergy 
method. The results were used to determine the sensitivity, specificity, negative predictive value and positive 
predictive value of the Vitek 2 ESBL test through comparative analysis with the combined disk synergy method 
which is the reference method recommended by CLSI. The findings of this work indicated that the sensitivity, 
specificity, positive predictive value and negative predictive value of Vitek 2 system was 98.5%, 98.9%, 99% 
and 98.5% respectively. Consequently, Vitek 2 system is a reliable semi-automated microbiology system which 
may be used for routine, accurate and rapid detection of ESBL strains in health facilities in Accra, Ghana.  
Keywords: Vitek 2 Compact System, Extended spectrum beta-lactamase, bioMérieux, E. coli and K.  pneumonia 
1.0 Introduction 
Extended-spectrum beta-lactamases (ESBLs) are plasmid-mediated beta-lactamases that are capable of 
hydrolysing β-lactams except carbapenems and cephamycins. They are inhibited by β-lactamase inhibitors such 
as clavulanic acid, sulbactam and tazobactam. They have been found in the Enterobacteriaceae and other Gram-
negative bacilli (Paterson and Bonomo, 2005). Kesah and Odugbemi (2002) reported more than 40% ESBL 
production among Enterobacteriaceae isolates in Lagos, Nigeria. In 2006, Olysegun and others (2006) also 
observed 50% ESBL production rate in K. pneumoniae isolates studied from Northwestern Nigeria. In Ghana, 
Adu-Sarkodie (2010) reported that EBSL has been isolated from 50.3% Klebsiella and 49.7% E. coli in Komfo 
Anokye Teaching Hospital, Kumasi. Outbreaks of infection with ESBL-producing organisms have been reported 
from virtually every European country (Hanberger et al., 1999). In some parts of Asia, the percentage of ESBL 
production in E. coli and K. pneumoniae varies from 4.8% in Korea (Pai et al., 1999) to 8.5% in Taiwan (Yan et 
al., 2000) and up to 12% in Hong Kong (Ho et al., 2005). ESBLs have been found in 30 to 60% of klebsiellae 
from intensive care units in Brazil, Colombia and Venezuela (Otman et al., 2002). The global increased 
prevalence of ESBL-producing bacteria creates an urgent need for laboratory diagnostic methods that will 
accurately and rapidly identify the presence of ESBL phenotypes in clinical isolates. Routine ESBL detection is 
highly recommended because some ESBL-producing organisms appeared susceptible to cephalosporins in vitro 
using conventional breakpoints but ineffective in vivo. A failure to detect ESBLs and subsequent treatment with 
oxyimino-cephalosporins are associated with a higher risk of therapy failure (Paterson et al., 2001). Other 
reports also indicate higher mortality rates (Kim et al., 2002).   The Clinical and Laboratories Standard Institute 
recommends a two-step phenotypic approach (CLSI, 2006), which involves screening for reduced susceptibility 
to more than one of the indicator antimicrobials (cefotaxime, ceftazidime, cefpodoxime, ceftriaxone, and 
aztreonam). After the ESBL screening test, the CLSI recommends the use of cefotaxime (30µg) or ceftazidime 
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disks (30µg) with clavulanate (10µg) for phenotypic confirmation of the presence of ESBLs in Klebsiella species 
and E. coli. The CLSI recommends that the disk tests should be performed with confluent growth on Mueller-
Hinton agar. A difference of ≥5mm between the zone diameters of either of the cephalosporin disks and their 
respective cephalosporin/clavulanate disk is taken to be phenotypic confirmation of ESBL production (CLSI, 
2006). The combined disk synergy method is accepted as a reference method for confirming ESBL-producing 
organism according to CLSI (CLSI, 2006). The Vitek 2 System (bioMérieux, France) is a rapid automated 
microbiological system used for bacteria and yeast identification, antimicrobial susceptibility testing (AST), 
resistance mechanism detection and epidemiologic trending and reporting. It analyses MIC patterns and detects 
bacterial resistance mechanisms and phenotypes for most organisms tested using its advanced expert system. 
Vitek 2 ESBL test is reported to serve as a phenotypic confirmatory tool for rapid detection of a positive or 
negative ESBL producing strain which is based on simultaneous assessment of the inhibitory effects of 
cefotaxime, ceftazidime and cefepime, alone and in the presence of clavulanic acid (Teresa et al., 2006). This 
present work seeks to determine the reliability of routinely using Vitek 2 System to accurately and rapidly detect 
ESBL-producing E. coli and K. pneumoniae in Accra by determining the sensitivity, specificity, negative 
predictive value and positive predictive value of the Vitek 2 ESBL test through comparative analysis with the 
combined disk synergy method.  
2.0 Materials and Methods 
2.1 Materials 
Glycerol broth, blood agar and MacConkey agar were prepared according to manufacturers’ guidelines.  MAST 
IDTM ESβL Detection Discs (Mast Group, UK) were used for ESBL screening and confirmation according to 
CLSI standards.  Vitek 2 Compact System (bioMérieux, Marcy I’Etoile, France) was also used to detect ESBL 
producers based on simultaneous assessment of the inhibitory effects of cefotaxime, ceftazidime and cefepime, 
alone and in the presence of clavulanic acid.  
2.2 Sample Size 
A sample size of 400 K. pneumoniae and E. coli were collected from the Central Laboratory of the Korle Bu 
Teaching Hospital (KBTH) and Advent Clinical Laboratories; both in the Accra Metropolis, Ghana. This 
corresponds with the standard techniques used to calculate the minimum sample size based on the expected 
prevalence and using appropriate levels of precision at 95% confidence level.  
2.3 Inclusion Criteria 
Non-duplicate pure cultures of K. pneumoniae and E. coli. 
2.4 Exclusion Criteria 
All isolates not confirmed as K. pneumoniae and E. coli. 
2.5 Identification of Bacterial Isolates and Determination of ESBL phenotypes using Vitek 2 System 
The lactose fermenting isolates were sub-cultured on blood and MacConkey agar and incubated at 35°C for 24 
hours. K. pneumoniae and E. coli were identified based on their Gram stain reaction and biochemical reaction 
characteristics using Vitek 2 system.  Sterile test tubes (ID and AST test tubes) used to prepare inoculums were 
filled with 3ml of 0.45% saline water and placed in a cassette. The identification (ID) test tube was used to 
prepare inoculum from the pure colonies and mixed thoroughly using a vortex until a suspension of 0.5 – 0.63 
McFarland was formed. The McFarland was determined using Densichek (bioMérieux, France). A volume of 
45µl of the inoculum from the ID test tube was pipetted into the antibiotic susceptibility testing (AST) test tube 
and mixed thoroughly. The Gram negative (GN) ID test cards and AST test cards were inserted in the respective 
test tubes and loaded into the Vitek instrument. While in the Vitek instrument, the cards were filled, sealed and 
incubated in the Vitek 2 system incubator until results were generated by the expert advanced system of the 
Vitek 2 system for the type of organism and ESBL phenotype. 
2.6 Detection of ESBL Phenotype using Combined Disc Synergy Method 
MAST IDTM ESβL Detection Discs (Mast Group, UK) were used to screen and confirm the ESBL phenotypes. 
The MAST IDTM ESβL Detection Discs comprise of cefpodoxime 30µg disks, cefpodoxime 30µg + clavulanic 
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acid 10µg disks; ceftazidime 30µg disks, ceftazidime 30µg + clavulanic acid 10µg disks and cefotaxime 30µg 
disks, cefotaxime 30µg + clavulanic acid 10µg disks. Using a pure culture of the test organism, a suspension in 
distilled water equivalent in density to a McFarland 0.5 opacity standard was prepared. Using a sterile swab, the 
suspension was spread uniformly across the surface of Mueller-Hinton agar plate. Using a sterile forceps, one of 
each MAST IDTM ESβL Detection Discs was placed onto the inoculated medium ensuring that they were evenly 
spaced. The plates were incubated aerobically at 35-37°C for 18 – 20 hours. The diameter of any zones of 
inhibition that were observed were measured and recorded. The zone of inhibition for the cefpodoxime, 
ceftazidime and cefotaxime was compared to that of the cefpodoxime, ceftazidime and cefotaxime plus 
clavulanic acid combination disks. An increase in zone diameter of ≥5mm in the presence of clavulanic acid 
from any or all of the sets of MAST IDTM ESβL Detection Discs indicates the presence of ESBL in the test 
organism. 
2.7 Statistical Analyses 
In comparison with results of the Combination Disk Synergy Method, the sensitivity of Vitek 2 ESBL test was 
calculated as the number of true positive ESBL divided by the sum of true positive and false negative ESBL X 
100. The specificity of Vitek 2 ESBL test was calculated as the number of true negative ESBL divided by sum of 
true negative and false positive ESBL X 100. The positive predictive value was calculated as number of true 
positives divided by the sum of true positive and false positives X 100. The negative predictive value was 
calculated as number of true negatives divided by sum of true negatives and false negatives X 100. The data 
from the work was collated and statistically analysed using one-way analysis of variance (ANOVA). Results 
were considered significant if p<0.05 
3.0 Results 
3.1 Bacterial Isolates 
Of the 400 bacterial isolates collected, 175 were K. pneumoniae and 225 were E. coli as shown by table 1. The 
bacterial isolates were produced from various clinical specimens submitted to the Korle Bu Central Laboratory 
and Advent Clinical Laboratories all in Accra.  
 
Table 1:                 Number of Bacterial Isolates  
                    K. pneumoniae             E. coli                        Total 
  
                    175 (43.7%)                 225 (56.3%)         400 (100%) 
  
3.2 ESBL Producing Phenotypes 
Two ESBL-producing detection methods (Vitek 2 ESBL test and combined disc synergy method) were used in 
determining the ESBL phenotypes of the bacterial isolates. The Vitek 2 ESBL test indicated that of the 175 K. 
pneumoniae isolates, 129 (73.7%) were ESBL producers and 73 (32.4%) of the 225 E. coli isolates were ESBL-
producing phenotypes. The total ESBL producing isolates detected by the Vitek 2 Compact System was 202 
representing 50.5% of the 400 bacterial isolates as demonstrated in table 2. The combined disc synergy method 
(CDM) detected 203 (50.8%) of ESBL producers among the 400 total bacterial isolates of which 130 (74.3%) of 
the 175 K. pneumoniae and 73 (32.4%) of the 225 E. coli isolates were ESBL producers as shown in table 2. 
There was no significant difference (p≥0.05) between the ESBL phenotypes detected by the combined disc 
synergy method and the Vitek 2 ESBL test in both the K. pneumoniae and E. coli isolates.  
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Table 2:                Occurrence of ESBL-producing Phenotypes 
                        
                                                          Number (%) 
                  ESBL Detection Method     K. pneumoniae         E. coli       All Isolates 
                                                                   n=175                n=225           n=400 
                  CDM                                          130(74.3)        73(32.4)      203(50.8)              
                 Vitek 2 System                           129(73.7)        73(32.4)       202(50.5) 
                 CDM: Combined Disk Synergy Method 
3.3 Non-ESBL Producing Phenotypes 
The Vitek 2 ESBL test indicated that of the 175 K. pneumoniae isolates, 46 (26.3%) were non-ESBL producers 
and 152 (67.5%) of the 225 E. coli isolates were non-ESBL producing organisms. The total non-ESBL 
producing isolates detected by the Vitek 2 Compact System was 198 representing 49.5% of the 400 bacterial 
isolates as demonstrated in table  3. The combined disc synergy method detected 197 (49.3%) of non-ESBL 
producers among the 400 total bacterial isolates of which 45 (25.7%) were K. pneumoniae and 152 (67.5%) were 
E. coli isolates as shown in table 3. 
Table 3:                         Distribution of Non-ESBL-Producing Phenotypes 
  
                                                                            Number (%) 
                 ESBL Detection Method        K. pneumoniae      E. coli          All Isolates 
                                                                        n=175              n=225           n=400 
                  CDM                                         45(25.7)             152(67.5)      197(49.3)              
                  Vitek 2 Compact                       46(26.3)             152(67.5)      198(49.5) 
                   CDM: Combined Disk Synergy Method 
 
3.4 Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value of Vitek 2 Compact System 
The reliability of Vitek 2 Compact System as an ESBL detection system was verified in comparison with the 
combined disk synergy method which is recommended by CLSI. As indicated in table 4, the true positive, true 
negative, false positive and false negative ESBL strains among the 400 bacterial isolates as detected by Vitek 2 
ESBL test were 200, 195, 2 and 3 respectively. Consequently, the sensitivity, specificity, positive predictive 
value and negative predictive value of Vitek 2 Compact System among the 400 bacterial isolates was 98.5%, 
98.9%, 99.0% and 98.5% respectively as shown in figure 1. 
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Table 4:         Reliability of Vitek 2 Compact as ESBL Detection System                       
                  Parameters                   K. pneumoniae          E. coli              All Isolates 
                                                        n=175                        n=225              n=400              
                 True Positive                      128                              72                   200 
                 True Negative                       44                           151                   195 
                 False Positive                          1                               1                       2 
                 False Negative                         2                               1                      3                                             
 
Figure 1: Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value of Vitek 2 Compact 
System 
4.0 Discussion 
VITEK 2 compact system (bioMérieux, Marcy I’Etoile, France) is a semi-automated bacterial identification and 
susceptibility testing system enabling rapid determination of MICs by analysis of bacteria growth kinetics with 
antimicrobials in sealed test cards and resistant mechanisms. This study aimed at establishing the reliability of 
VITEK 2 compact system to detect ESBLs in clinical isolates of K. pneumoniae and E. coli in comparative 
analysis with combined disk method. In a comparative study with CLSI method of detecting ESBL, Sorlozano 
and colleagues (2005) observed that the sensitivity (100%), specificity (99.3–100%), and predictive values of the 
disk approximation, Etest and VITEK 2 methods were similar. This outcome is comparable to the sensitivity 
(98.5%), specificity (98.9%), positive predictive value (99%) and negative predictive value (98.5%) of Vitek 2 
system as observed in this present work. The sensitivity and specificity values obtained were somewhat better 
than those reported by Leverstein-van Hall et al. (2002) (100% sensitivity, 87% specificity), Sanders et al., 
(2000) (91% sensitivity), and Livermore et al. (2002) (93% sensitivity), although these studies evaluated ESBL 
positive strains belonging to various species other than K. pneumoniae and E. coli. Nevertheless, they concluded 
that VITEK-2 compact showed an acceptable reliability to detect ESBL-producing K. pneumoniae and E. coli. 
Wiegand and colleagues (2007) compared the ability of three commercially available semi-automated 
microbiology identification and susceptibility testing systems [Phoenix Automated Microbiology System (BD 
Diagnostic Systems, Sparks, MD), the VITEK 2 System (bioMérieux, Marcy l'Etoile, France) and the MicroScan 
WalkAway-96 System (Dade Behring, Inc., West Sacramento, CA)] to detect ESBL production in 
Enterobacteriaceae using routine testing panels. The bacterial isolates investigated included Escherichia coli, 
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Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, 
Serratia marcescens, Proteus mirabilis, Proteus vulgaris and Morganella morganii. Of these 147 isolates used, 
85 were identified as ESBL producers by the reference method. The system with the highest sensitivity for the 
detection of ESBLs was the Phoenix (99%), followed by the VITEK 2 (86%) and the MicroScan (84%); 
however, specificity was more variable, ranging from 52% (Phoenix) to 78% (VITEK 2). The performance of 
the semi-automated systems differed widely with the species investigated (Wiegand et al., 2007). This outcome 
contradicts the sensitivity and specificity values observed in this present work. 
However, a work published by Teresa and colleagues (2006) which agreed with the outcome of this present work 
suggested that Vitek 2 system appears to be a rapid and reliable tool for routine identification of ESBL-
producing isolates of Enterobacteriaceae. They examined a total of 1,129 clinically relevant Enterobacteriaceae 
isolates for ESBL producing using Vitek 2 system and molecular method and the results concluded that the 
VITEK 2 ESBL test system was concordant with that of the comparison method (molecular identification of 
beta-lactamase genes) for 1,121 (99.3%) of the 1,129 isolates evaluated. ESBL production was correctly detected 
in 306 of the 312 ESBL-producing organisms (sensitivity, 98.1%; positive predictive value, 99.3%). False-
positive results emerged for 2 of the 817 ESBL-negative isolates (specificity, 99.7%; negative predictive value, 
99.3%). VITEK 2 ESBL testing took 6 to 13 h (median, 7.5 h; mean ± SD, 8.2 ± 2.39 h) (Teresa et al., 2006).  
5.0 Conclusion 
The findings of this work indicated that the sensitivity, specificity, positive predictive value and negative 
predictive value of Vitek 2 system was 98.5%, 98.9%, 99% and 98.5% respectively in comparison with the 
combined disc synergy method which is the reference method as recommended by CSLI. Consequently, Vitek 2 
sytem is a reliable semi-automated microbiology system which may be used for routine, accurate and rapid 
detection of ESBL strains in health facilities in our settings. 
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